The European Commission has approved Cenrifki (tolebrutinib) by Sanofi for treating secondary progressive multiple sclerosis (SPMS) without relapses, based on positive phase 3 trial results showing it delays disability progression. This is the first drug approved in the EU to specifically target the underlying progression of disability in SPMS patients without recent relapses. Cenrifki works by inhibiting brain-penetrant Bruton tyrosine kinase to reduce neuroinflammation, a key factor in SPMS progression. Sanofi plans to launch Cenrifki commercially in Germany this year, with close medical oversight and risk management to ensure patient safety, especially monitoring liver enzyme elevations linked to the drug.
